Introducing: Derek Ellison, Principal Commercial Consultant
Posted on 19 Aug 2026
GreyRigge Associates welcome senior biopharmaceutical industry leader Dr. Derek Ellison into GreyRigge Associates as Principal Commercial Consultant. Following a long and successful career in biopharmaceutical development, manufacturing and commercial leadership, Derek brings his deep domain expertise and extensive CMC know-how to GreyRigge and our clients.
Derek's background is baked in the establishing and leading successful commercial CDMO businesses. His experience spans asset transition, CDMO optimisation, contract manufacturing and commercial leadership, making him an ideal partner for our clients. For us, Derek’s role will spread across three areas:
- Delivering CMC/manufacturing strategy and commercialisation, helping clients optimise development and manufacturing strategies and progress assets towards commercialisation.
- Board Advisor to assist GreyRigge with its growth and decisions on strategy, investment and the continuing development of our consultancy services.
- Developing strategic client relationships and identifying opportunities where GreyRigge can add value.
On announcing Derek's, involvement with us, our co-founder and EMEA Managing Partner Samantha Dowse commented:
“I've known and admired Derek for many years. He has an excellent understanding of the complex needs of our clients in our industry, combined with an ability to build a successful business and lasting client relationships. His combination of technical, commercial and leadership experience will be invaluable to both GreyRigge and our clients."
Working with Derek reflects our commitment to involving top industry talent in our organisation as we scale globally.
View more blog posts
01
AI in Regulatory Affairs: What our Panel Conversations Are Actually Revealing
On a Panel at Pharma Tech Summit 2026, we discussed multiple perspectives around AI usage in biotech. Here's what we learned.
02
Common Module 3 Pitfalls: Why Your CMC Data Isn’t Submission-Ready
Intense timeline brought on in CMC development makes life for small, and phase 1 biotechs difficult, leading to developers letting their Module 3 dossier fall away. Understand the common problems we see, to prevent them for your submission.
03
Building Biotech: How Nigeria can become the Vaccine Powerhouse in Africa
Lee Smith and Oyeronke Oyebanji sat down with BioProcess Insider to discuss the vaccine development and delivery practices in Nigeria: the good, the bad, and the path forward.
04
Live Attenuated Viral Vaccines Advancements
Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe.
05
Hope for Chlamydia STI Vaccine After Promising Initial Results
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials.
06
GreyRigge Associates partners with NG Bio to accelerate VC investment
NG Bio and GreyRigge Associates Announce Strategic Partnership to Advance Biotech Innovation
07
Gene Therapy for Rare Disorders
Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy.
08
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
CEPI awards US$21 million to Themis Bioscience.
09
Greyrigge Associates partner with SciPot Consultancy
GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy
010
Building Biotech: Being ready for AI
AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.
011
Building Biotech: How COVID-19 changed development forever
The COVID-19 pandemic transformed vaccine development by compressing timelines from decades to months, proving that rapid innovation is possible through parallel development, adaptive regulation, and unprecedented global equity.
012
Building Biotech: Animal Models and Beyond - What's Next?
Animal models have long underpinned vaccine development by enabling preclinical evaluation of immunogenicity, efficacy, safety, and dose selection, and they remain integral to regulatory submissions and certain approval pathways such as the FDA Animal Rule.
013
Crucial Considerations for winning biotech investment in FY 2026
Commercial strategy is always considered too late. Without having an end image in mind, it creates problems across operations during the development process, not the least being investors don't know what they're investing in.